Cocaine Use Disorder (CUD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Cocaine Use Disorder (CUD) Market Outlook

Thelansis’s “Cocaine Use Disorder (CUD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cocaine Use Disorder (CUD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cocaine Use Disorder (CUD) Overview

Cocaine use disorder (CUD) is a significant global public health issue characterized by the compulsive use of cocaine despite its detrimental medical, psychological, and behavioral effects. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), defines CUD as the presence of at least 2 out of 11 criteria causing clinically significant impairment or distress within 12 months. These criteria can be categorized into four groups: physiological (craving, tolerance, and withdrawal), loss of control, prioritization of cocaine over other activities, and negative consequences resulting from cocaine use. The severity of CUD is determined by the number of symptoms present: mild CUD is indicated by two or three symptoms, moderate CUD by four or five symptoms, and severe CUD by six or more symptoms. Continued cocaine use over time carries a high risk of progressing to CUD, particularly among individuals who initiate cocaine use around the age of 20. This younger population often struggles with long-term cessation efforts. Numerous risk factors contribute to the development of CUD, including genetic, environmental, and demographic factors. The hereditary influence on CUD susceptibility is estimated to be up to 65% in women and up to 79% in men. Cocaine’s acute effects play a role in driving habitual patterns of use. As a psychostimulant, cocaine stimulates the sympathetic nervous system, resulting in heightened arousal, increased activity, enhanced mood, reduced appetite, and sleep disturbances. Higher doses and faster routes of administration (such as smoking or intravenous injection) can intensify euphoria, thereby increasing the likelihood of addiction development. Individuals with CUD encounter various barriers when seeking treatment; most do not receive the necessary interventions. Currently, no pharmacological treatments are approved by the U.S. Food and Drug Administration (FDA) for CUD.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Cocaine Use Disorder (CUD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034